Please login to the form below

Not currently logged in
Email:
Password:

cost

This page shows the latest cost news and features for those working in and with pharma, biotech and healthcare.

Shionogi scores FDA approval for new cUTI antibiotic

Shionogi scores FDA approval for new cUTI antibiotic

The development of new drugs to treat antibiotic resistant germs is well overdue, as pharma companies have halted research in this area as there is no significant payback for the cost

Latest news

More from news
Approximately 9 fully matching, plus 2,807 partially matching documents found.

Latest Intelligence

  • Strengthening business competition and reducing anti-competitive practices Strengthening business competition and reducing anti-competitive practices

    Cost: both in terms of reduced fines (settling companies can and commonly do achieve a maximum discount on potential penalty of 20%) and saving/better utilising resources (settling with the CMA ... means committing to a streamlined administrative process

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe asthma subtypes, represent 50% of the cost of asthma care expenditure.

  • Delivering the promise of regenerative medicine Delivering the promise of regenerative medicine

    but only for a limited time period. By streamlining the currently very expensive manufacturing process and improving supply chain management, yields will automatically get larger and costs will slowly come down.

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    Input from industry insiders and experts identified a range of concerns associated with annuity payment models, including a potentially significant impact on cost of capital and company valuations, costs and burden ... The financial impact of annuity

  • Creating value from value-based healthcare Creating value from value-based healthcare

    An opportunity or a threat for pharma? On the surface, VBHC appears to be an opportunity predominantly for policymakers to achieve better health outcomes at a lower cost. ... The companies that are able to identify the systems and stakeholders willing to

More from intelligence
Approximately 1 fully matching, plus 460 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 348 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics